A Leader in the Discovery and Development of Small Molecules that Disrupt Protein-Protein Interactions

Ascentage is a globally-focused, clinical-stage biopharma developing novel therapies for cancers, hepatitis B & age-related diseases. Our expertise is in developing inhibitors of protein-protein interactions (PPIs) to restore apoptosis, or programmed cell death. We have seven drug candidates in Phase I or II clinical trials in the U.S., Australia and China, including a novel Bcl-2/Bcl-xL inhibitor as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors (TKIs).

Learn More

Targeting Key Regulatory Proteins
in Apoptotic Pathways

BCL2

MDM2

MDM2-p53

Global Clinical Trials

Learn More

San Antonio, TX

San Diego, CA

Rochester, MN

Ann Arbor, MI

Cleveland, OH

Philadelphia, PA

Baltimore, MD

Beijing

Suzhou

Guangzhou

Nedlands, AU

Camperdown, AU